When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study
Resuming antitumor therapy early after SARS-CoV-2 test turned negative did not increase antitumor therapy-related AEs or the incidence of re-infection in COVID-19 infection patients.
Authors
- Xiaofen Pan (ORCID: https://orcid.org/0000-0002-0773-0976)
- Jiehao Liao
- Gan Huang (ORCID: https://orcid.org/0000-0002-7595-973X)
- Wei Wang (ORCID: https://orcid.org/0009-0003-7539-9394)
- Xueying Li (ORCID: https://orcid.org/0000-0002-1100-4694)
- Mengyuan Zhu (ORCID: https://orcid.org/0000-0003-4825-4168)
- Shan Huang (ORCID: https://orcid.org/0000-0002-1621-5589)
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1007/s00520-025-09333-9
- Citations
- 1
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Sun Yat-sen University
- Basic and Applied Basic Research Foundation of Guangdong Province